You just read:

Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension Frequently Found in Thoroughbred Horses

News provided by

Entest BioMedical Inc.

Jan 10, 2017, 08:00 ET